Beclometasone dipropionate extrafine aerosol versus fluticasone propionate in children with asthma

Respiratory Medicine

Volumn 101, Issue 7, 2007, Pages 1585-1593

  van Aalderen, W M C ^a   Price, D ^b   De Baets, F M ^c   Price, J ^d  

^a EMMA CHILDREN S HOSPITAL   (Netherlands)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

^c GHENT UNIVERSITY HOSPITAL   (Belgium)

^d KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Administration inhalation; Asthma; Beclometasone diproprionate; Children; Extrafine aerosol; HFA 134a

Indexed keywords

ANTIHISTAMINIC AGENT; BECLOMETASONE DIPROPIONATE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CHLOROFLUOROCARBON; FLUTICASONE PROPIONATE; STEROID;

AEROSOL; ARTICLE; ASTHMA; ATTENTION DISTURBANCE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DISEASE CONTROL; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FORMULATION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPHONIA; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; HYPERACTIVITY; INHALATION SPACER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OROPHARYNX CANDIDIASIS; PALLOR; PATIENT COMPLIANCE; PEAK EXPIRATORY FLOW; PHARYNGITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UPPER RESPIRATORY TRACT INFECTION;

ADMINISTRATION, INHALATION; AEROSOLS; ANDROSTADIENES; ANTI-ASTHMATIC AGENTS; ASTHMA; BECLOMETHASONE; BRONCHODILATOR AGENTS; CHILD; CHILD, PRESCHOOL; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; QUALITY OF LIFE; RESPIRATORY MECHANICS; TREATMENT OUTCOME;

EID: 34249664522     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2006.11.020     Document Type: Article

References (27)

1. The Montreal Protocol. The Montreal Protocol on substances that deplete the ozone layer. Final Act (Nairobi: UNEP 1987). Federal Reg 59 (1994) 56276-56298
2. Leach C.L. Effects of formulation parameters on hydrofluoroalkane-beclomethasone dipropionate drug deposition in humans. J Allergy Clin Immunol 104 (1999) S250-S252
3. Leach C.L., Davidson P.J., and Boudreau R.J. Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone. Eur Respir J 12 (1998) 1346-1353
4. Van Schayck C.P., and Donnell D. The efficacy and safety of QVAR (hydrofluoroalkane-belcometasone dipropionate extrafine aerosol) in asthma (Part 2): clinical experience in children. Int J Clin Pract 58 (2004) 786-794
5. Davies R.J., Stampone P., and O'Connor B.J. Hydrofluoroalkane-134a beclomethasone dipropionate extrafine aerosol provides equivalent asthma control to cholorfluorocarbon beclomethasone dipropionate at approximately half the total daily dose. Respir Med 92 Suppl A (1998) 23-31
6. Gross G., Thompson P.J., Chervinsky P., Vanden Burgt J., and and the study group. Hydrofluoroalkane-134a beclomethasone dipropionate, 400 μg, is as effective as chlorofluorocarbon beclomethasone dipropionate, 800 μg, for the treatment of moderate asthma. Chest 115 (1999) 343-351
7. Fireman P., Prenner B.M., Vincken W., Demedts M., Mol S.J., and Cohen R.M. Long-term safety and efficacy of a chlorofluorocarbon-free beclomethasone dipropionate extrafine aerosol. Ann Allergy Asthma Immunol 86 (2001) 557-565
8. Reichel W., Dahl R., Ringdal N., Zetterstrom O., van den Elshout F.J., and Laitinen L.A. Extrafine beclomethasone dipropionate breathe-actuated inhaler (400 mcg/day) versus budesonide dry powder inhaler (800 mcg/day) in asthma. Int J Clin Pract 55 (2001) 100-106
9. Szefler S.J., Warner J., Staab D., et al. Switching from conventional to extrafine aerosol beclomethasone dipropionate therapy in children: a 6-month, open label, randomized trial. J Allergy Clin Immunol 110 (2002) 45-50
10. Worth H., Muir J., and Pieters W. Comparison of hydrofluoroalkane beclomethasone dipropionate Autohaler with budesonide Turbuhaler in asthma control. Respiration 68 (2001) 517-526
11. Scheinmann P, Staab D, de Boeck C, et al. A double-blind comparison of budesonide (B) and beclomethasone extrafine aerosol (Q) in children with symptomatic asthma. Allergy 2003; 58 (suppl 135): 74 (abstract 445).
12. Aubier M., Wettenger R., and Gans S.J. Efficacy of HFA-beclomethasone dipropionate extra-fine aerosol (800 μg/day) versus HFA-fluticasone propionate (1000 μg/day) in patients with asthma. Respir Med 95 (2001) 212-220
13. Fairfax A., Hall I., and Spelman R. A randomized, double-blind comparison of beclomethasone dipropionate extrafine aerosol and fluticasone propionate. Ann Allergy Asthma Immunol 86 (2001) 575-582
14. Juniper E.F., Guyatt G.H., Feeny D.H., Ferrie P.J., Griffith L.E., and Townsend M. Measuring quality of life in children with asthma. Qual Life Res 5 (1996) 35-46
15. Juniper E.F., Guyatt G.H., Feeny D.H., Ferrie P.J., Griffith L.E., and Townsend M. Measuring quality of life in the parents of children with asthma. Qual Life Res 5 (1996) 27-34
16. Ebbutt A.F., and Frith L. Practical issues in equivalence trials. Stat Med 17 (1998) 1691-1701
17. Goldin J.G., Tashkin D.P., Kleerup E.C., et al. Comparative effects of hydrofluoroalkane and chlorofluorocarbon beclomethasone dipropionate inhalation on small airways: assessment with functional helical thin-section computed tomography. J Allergy Clin Immunol 104 (1999) S258-S267
18. Lyttle B., Gilles J., Panov M., Emeryk A., and Wixon C. Fluticasone propionate 100 microg bid using a non-CFC propellant, HFA-143a, in asthmatic children. Can Respir J 10 (2003) 103-109
19. Jonasson G., Carlsen K.-H., and Blomqvist P. Clinical efficacy of low-dose inhaled budesonide once or twice daily in children with mild asthma not previously treated with steroids. Eur Respir J 12 (1998) 1099-1104
20. Merkus P.J.F.M., Kerrebijn K.F., and Quanjer P.H. Evolution of therapy for childhood asthma. Am Rev Respir Dis 148 (1993) 818-819
21. Global Initiative for Asthma. Asthma management and prevention: a practical guide for Public Health Officials and Health Care Professionals (based on the global strategy for asthma management and prevention NHLBI/WHO workshop report). 〈http://www.ginasthma.com/GuidelineItem.asp?intId=819〉. Date last updated: 2004. Date last accessed: July 6, 2005.
22. British Thoracic Society and Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma. A national clinical guideline, revised ed. 〈http://www.brit-thoracic.org.uk〉www.brit-thoracic.org.uk. Date last updated: April 2004. Date last accessed: July 19, 2005.
23. SmPc for Qvar. The Netherlands. 〈http://www.cbg-meb.nl/nl/overcbg/index.htm〉 Date last updated: May 24, 2006. Date last accessed: June 20, 2006.
24. Duiverman E.J., Brackel H.J., Merkus P.J., Rottier B.L., and Brand P.L. Sectie Kinderlongziekten van de Nederlandse Vereniging voor Kindergeneeskunde. Guideline 'Treating Asthma in Children' for Pediatric Pulmonologists (2nd revised edition), II: medical treatment. Ned Tijdschr Geneeskd 147 (2003) 1909-1913
25. Randell T.L., Donaghue K.C., Ambler G.R., Cowell C.T., Fitzgerald D.A., and van Asperen P.P. Safety of the newer inhaled corticosteroids in childhood asthma. Pediatr Drugs 5 (2003) 481-504
26. Nayak A., Lanier R., Weinstein S., Stampone P., and Welch M. Efficacy and safety of beclomethasone dipropionate extrafine aerosol in childhood asthma: a 12-week, randomized, double-blind, placebo-controlled study. Chest 122 (2002) 1956-1965
27. Pedersen S., Warner J., Wahn U., et al. Growth, systemic safety, and efficacy during 1 year of asthma treatment with different beclomethasone dipropionate formulations: an open-label, randomized comparison of extrafine and conventional aerosols in children. Pediatrics 109 (2002) e92